HBOT (Hyperbaric Oxygen Therapy)

No. Soft-chamber mHBOT at 1.3-1.5 ATA and hard-chamber HBOT at 2.0-2.4 ATA are mechanistically and regulatorily distinct. The FDA cleared soft chambers (1.3 ATA) ONLY for acute mountain sickness transport. The UHMS, AMA, and FDA agree that 1.3 ATA sits below the conventional therapeutic threshold. The the DoD HOPPS trial and the BIMA trial tested soft-chamber pressures for mTBI / persistent post-concussion syndrome and were NEGATIVE on primary endpoints. The VA/DoD Clinical Practice Guideline explicitly recommends AGAINST HBOT for persistent post-concussion symptoms, and the DoD's in TBI Center of Excellence Information Paper maintains that recommendation. Soft-chamber units are useful for reaching patients in remote settings and for the narrow AMS transport indication, but marketing them for longevity, cognitive aging, or off-label cosmetic outcomes runs against the published evidence.

Aviv Clinics charges $51,500-90,000 for the full 60-session 2.0 ATA × 90 min protocol. The strongest supporting evidence is Hadanny 2020 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377835/), an n=63 RCT in healthy adults 64+ that showed attention effect size d=0.745, processing speed d=0.788, and prefrontal / parietal cerebral blood flow improvements. The same protocol underlies the Hachmo 2020 telomere study, which has documented methodological flaws and direct Aviv financial conflicts (Hadanny employed by the Aviv lab Ltd, Efrati shareholder and Medical Advisory Board Chair). Aviv raised $40M Series B in in Q3 . Tony Robbins co-founded Fountain Life with Peter Diamandis offering similar premium HBOT packaging. The cognitive signal is real for the indicated population (cognitive decline, 60+). The cost-per-effect-size dollar is hard to defend against alternatives like aerobic training plus targeted nutrition. Worth it if the user has the budget AND a quantifiable cognitive complaint AND realistic expectations about reversibility.

No. Hachmo 2020 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746357/) reported telomere lengthening and senescent cell reduction after 60 hard-chamber sessions, and the result has zero independent replication in 5+ years. Nick Brown's in Q4 statistical critique on forbetterscience.com identifies non-independent samples treated as independent (the same 30 subjects measured at multiple time points), a GRIM violation in Table 1, and unjustified exclusion of 4 telomere samples plus 10 senescent-cell samples. The authors have direct financial conflicts: Hadanny was employed by the Aviv lab Ltd, and Efrati holds Aviv shares plus chairs the Medical Advisory Board. Aviv raised $40M Series B in in Q3 promoting the protocol commercially. The biological plausibility is not zero (HIF-1α modulation, eNOS-dependent stem cell mobilization), but the specific Hachmo finding should be cited with the structural compromise honestly disclosed, not as established fact.

The evidence is contested and the official guidance is negative. Three sham-controlled trials (the DoD HOPPS trial , the BIMA trial, HOPPS) failed to beat sham on primary endpoints for mTBI / persistent post-concussion. The VA/DoD Clinical Practice Guideline explicitly recommends AGAINST HBOT for persistent post-concussion symptoms, and the DoD's in TBI Center of Excellence Information Paper maintains that position. Paul Harch and others argue (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968958, PMC8968958) that the 1.2-1.3 ATA control arms used in those trials were biologically active rather than true shams, and that the studies effectively compared two doses of HBOT. That argument is mechanistically plausible but does not constitute positive evidence. The NCT06581003 USF Florida $28M veterans trial (n=420 at 2.0 ATA × 40 sessions, completion ~) is the largest TBI study ever launched and may resolve the question. Until then, off-label TBI use is paying for the hope.

For most longevity and cognitive aging buyers, no. Soft-chamber units (OxyHealth Vitaeris 320, Summit-to-Sea, Sechrist, $4,000-20,000) cap at 1.3-1.5 ATA. That pressure is FDA-cleared only for AMS transport and sits below the conventional therapeutic threshold. The clinical RCTs supporting cognitive aging (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377835), fibromyalgia (https://pubmed.ncbi.nlm.nih.gov/26010952/), and post-stroke (https://pubmed.ncbi.nlm.nih.gov/23335971/) all used 2.0 ATA hard-chamber pressure. Soft chambers cannot reach those pressures. They may produce some hyperoxic exposure, and Harch argues 1.3 ATA is biologically active, but the evidence to back that for off-label longevity outcomes does not exist. MAUDE database reports document zipper failures and other mechanical issues. If the use case is recovery from documented concussion or chronic mild TBI under supervision, soft chambers may have a role, but generic at-home longevity buyers are paying $10,000+ for a pressure tier that cannot be marketed for the outcomes they want.

Bleomycin chemotherapy creates synergistic pulmonary toxicity with hyperbaric oxygen. The mechanism is hyperoxia-driven amplification of bleomycin-induced lung fibrosis: oxygen radicals interact with bleomycin metabolites to accelerate alveolar damage. Animal data on concurrent doxorubicin shows 87% rat mortality. UHMS and most clinical hyperbaric medicine programs require a 3-6 month washout from bleomycin before HBOT, and many decline the patient entirely if there is any suspicion of recent exposure. Other chemotherapy contraindications include doxorubicin, cisplatin, and disulfiram. The clinical rule: any patient with a history of bleomycin exposure must be cleared by a pulmonologist with documented PFTs before any hyperbaric exposure, even for a UHMS-approved indication. This is not a theoretical concern. The ABSOLUTE contraindication is one of the few absolute rules in hyperbaric medicine.

The evidence just got worse. Efrati 2022 (n=73) and the 1-year follow-up (https://pubmed.ncbi.nlm.nih.gov/38360929/) reported positive cognitive and fatigue outcomes from a 2.0 ATA × 60-session protocol in long-COVID patients. The HOT-LoCO 2025 trial (https://pubmed.ncbi.nlm.nih.gov/40228859/) from Karolinska Institutet is a sham-controlled RCT (n=80) at 2.4 ATA × 90 min × 10 sessions, and it was NEGATIVE on both primary endpoints: RAND-36 Physical Functioning (p=0.87) and Role Limitations (p=0.57). HOT-LoCO is the highest-quality direct test of HBOT for long COVID published to date and it directly contradicts the Efrati findings at the same pressure tier. Differences in protocol length (10 vs 60 sessions) may explain some variance, but the negative result raises serious questions about whether the Efrati positive signal survives independent replication. Long-COVID buyers should be told this honestly before signing up for $50,000+ programs.

Bryan Johnson documented 60 hard-chamber sessions in in X posts, running the Efrati / Aviv 2.0 ATA × 90 min protocol. The protocol he ran is the same one underlying Hadanny 2020 (cognitive aging) and Hachmo 2020 (telomere claim). It is the most-evidenced longevity protocol in HBOT, and he is in the population (40+) where Hadanny showed effects. Three caveats: (1) the Hachmo telomere result has documented methodological flaws and zero replication; (2) HOT-LoCO 2025 just contradicted the Efrati post-COVID arm at the same pressure; (3) the cost is $50,000+ if running through Aviv. Johnson runs Blueprint as a public n=1 experiment, not as evidence. Following his exact protocol is reasonable IF the user has the budget, an actual cognitive-aging complaint or biological-age intervention budget, and is genuinely interested in HBOT as a therapy rather than as identity signaling. For most readers, the same dollars allocated to sleep, exercise, and cardiometabolic risk reduction return more biological-age points per dollar.